Oxidative Stress, Hypertension and an FGF-binding Protein

氧化应激、高血压和 FGF 结合蛋白

基本信息

  • 批准号:
    7218285
  • 负责人:
  • 金额:
    $ 33.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

Fibroblast growth factors (FGF-1 or -2) are present at significant concentrations in most normal tissues in the adult. However, these FGFs are immobilized in an inactive state on the extracellular matrix and it is only poorly understood how they are solubilized and activated to reach their extracellular receptors. One mechanism through which FGFs can be mobilized is by binding to secreted binding proteins (BPs) and we showed that BP1 can enhance the activity of locally stored, immobilized FGFs. BP1 expression is controlled by stress pathways in cultured cells and found upregulated after wounding, toxic or infectious injury of the skin or kidneys. BP1 expression in mice carrying an inducible BP1 transgene caused a significant rise in mean arterial blood pressure (MAP) by +30 mm Hg within two days of transgene induction and analysis of vascular contractility showed a sensitization to angiotensin II. The rise of MAP after BP1 transgene expression was inhibited by systemic administration of the superoxide dismutase mimetic Tempol suggesting an essential role of oxidative stress. We hypothesize that BP1/FGF signaling modulates the sensitivity of blood vessels towards contractile signaling and propose to study this under the following aims: Aim 1. To evaluate the contribution of FGF-2 or other FGFs to the BP1-induced hypertensive effect. We will study blood pressure, vessel contractility and renal tubular function in FGF-2(-/-) mice that are crossed with mice carrying an inducible BP1 transgene. Systemic administration of BP1 and FGF-2 will complement this. Aim 2. To study the contribution of kidney expression of BP1 to blood pressure regulation, vessel contractility and renal tubular function we will use mice harboring a HoxB7-controlled, tetracycline inducible BP1 transgene. To evaluate the role of endogenous BP1 to oxidative stress-regulated blood pressure, we will generate mice that are null for BP1 expression. Aim 3. To study the intracellular cross-talk between BP1 / FGF signaling and G-protein coupled receptor pathways we will monitor signal transduction and phenotypic effects in preglomular smooth muscle cells from experimental animals. Biochemical signaling via known integrators of the pathways (i.e. MAPKs) and proliferation/cell survival and superoxide generation will be used as read-outs. Mass spectrometry to identify new signaling proteins in the cross-talk will complement this.
成纤维细胞生长因子(FGF-1或-2)存在于大多数正常组织中

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anton Wellstein其他文献

Anton Wellstein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anton Wellstein', 18)}}的其他基金

Oxidative Stress, Hypertension and an FGF-binding protein
氧化应激、高血压和 FGF 结合蛋白
  • 批准号:
    8148030
  • 财政年份:
    2010
  • 资助金额:
    $ 33.47万
  • 项目类别:
Pancreas Cancer Specialized Prog of Research Excellence
胰腺癌专业卓越研究计划
  • 批准号:
    6800656
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Inhibition of the ALK Receptor Kinase
ALK 受体激酶的抑制
  • 批准号:
    6933054
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Pancreas Cancer Specialized Program of Research Excelle*
Excelle 胰腺癌专门研究计划*
  • 批准号:
    6937066
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Pancreas Cancer Specialized Program of Research Excelle*
Excelle 胰腺癌专门研究计划*
  • 批准号:
    7108549
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Pancreas Cancer Specialized Program of Research Excelle*
Excelle 胰腺癌专门研究计划*
  • 批准号:
    7247994
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Inhibition of the ALK Receptor Kinase
ALK 受体激酶的抑制
  • 批准号:
    6770220
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Pancreas Cancer Specialized Program of Research Excelle*
Excelle 胰腺癌专门研究计划*
  • 批准号:
    6804998
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Inhibition of the ALK Receptor Kinase
ALK 受体激酶的抑制
  • 批准号:
    7095980
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:
Inhibition of the ALK Receptor Kinase
ALK 受体激酶的抑制
  • 批准号:
    6669574
  • 财政年份:
    2003
  • 资助金额:
    $ 33.47万
  • 项目类别:

相似海外基金

Acute Kidney Failure in a Cancer ICU
癌症 ICU 中的急性肾衰竭
  • 批准号:
    7034020
  • 财政年份:
    2006
  • 资助金额:
    $ 33.47万
  • 项目类别:
Acute Kidney Failure in a Cancer ICU
癌症 ICU 中的急性肾衰竭
  • 批准号:
    7459945
  • 财政年份:
    2006
  • 资助金额:
    $ 33.47万
  • 项目类别:
Acute Kidney Failure in a Cancer ICU
癌症 ICU 中的急性肾衰竭
  • 批准号:
    7922716
  • 财政年份:
    2006
  • 资助金额:
    $ 33.47万
  • 项目类别:
Acute kidney failure: investigation and treatment of ki dney cell injury
急性肾衰竭:肾细胞损伤的调查和治疗
  • 批准号:
    nhmrc : 901011
  • 财政年份:
    1990
  • 资助金额:
    $ 33.47万
  • 项目类别:
    NHMRC Project Grants
Acute kidney failure: new methods of investigation and treatment
急性肾衰竭:研究和治疗的新方法
  • 批准号:
    nhmrc : 891081
  • 财政年份:
    1989
  • 资助金额:
    $ 33.47万
  • 项目类别:
    NHMRC Project Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了